Fostering public engagement in the ethical and social implications of genetic technologies

23andMe: Screening a Personalised Medicine Company for Ethical Problems

With the information that our genomes hold we can make better decisions and be more proactive when it comes to our health. We can now personalise medicine. 23andMe, the Google-backed personal genetics company, are working towards exactly that. According to their co-founder, 23andMe promises nothing less than to “revolutionize health care”. They have certainly made an impression: since launching their Personal Genome Service in 2008 (initially costing £636, now £125), 23andMe has received Time magazine’s Invention of the Year award and amassed 650,000 genotypes from customers – the largest single collection of DNA in existence. But their revolution has not gone entirely as planned. With controversy following controversy, last November 23andMe were forced to stop selling their genetic testing products in the US. Consequently they have explored the possibility of marketing ...

Twitter Feed

Ethicsand @Ethicsand report on genetic privacy and the commercialisation of genetic data - covered by the Guardian… … …

Friday, 05 July 2013 via web • 3 retweets

Ethicsand Caldicott2 was not an independent review of privacy. Privacy laws have been redefined by the commercialization of personal data @Ethicsand

Friday, 05 July 2013 via web • 1 retweet

Ethicsand All #NHS users can now, by default, have their medical records accessed by pharma companies, to take part in clinical trials. Happy 65th!

Friday, 05 July 2013 via web • 6 retweets

Most Popular